5.1 Encasement Without Compression

Malignant infiltration can encase the ureters, preventing both urine flow and ureteral dilation. The surrounding tumor mass creates a rigid environment that restricts collecting system expansion even as obstruction develops (9,10).

5.2 Acute Obstruction

Hydronephrosis requires time to develop. In acute complete obstruction, imaging performed within 6–24 hours may precede visible dilation (1,3).

5.3 Volume Depletion

Patients with significant intravascular volume depletion produce less urine, limiting the distending pressure needed to cause hydronephrosis (1,6).

5.4 Reduced Baseline GFR

Patients with pre-existing CKD or severely reduced GFR from any cause produce less urine and are therefore less likely to develop detectable hydronephrosis (1,6).

6.1 Ultrasound Limitations and Pitfalls

Renal ultrasound remains the first-line imaging modality for evaluating AKI, but its limitations in detecting obstruction are well-documented:

Causes of false-negative ultrasound include: acute obstruction occurring less than 6–24 hours prior to imaging, significant volume depletion reducing urine output, encasement by tumor or fibrosis preventing dilation, reduced baseline GFR limiting urine production, and operator or technical factors in bedside imaging (3,4,11,12).

6.2 Renal Resistive Index

Doppler ultrasound can provide functional information beyond anatomic assessment. The renal resistive index (RI) is calculated as (peak systolic velocity – end diastolic velocity) / peak systolic velocity.

Diagnostic performance of RI for obstruction: sensitivity 85–93%, specificity 67–77% (13,14). However, RI is affected by numerous factors including intrinsic renal disease, ATN, hypotension, and heart rate, limiting its specificity (15,16).

Clinical Pearl: An elevated RI (>0.70) in the setting of clinical suspicion for obstruction but absent hydronephrosis should prompt further investigation. However, a normal RI does not exclude obstruction, and the test has significant limitations (13–16).

6.3 CT Secondary Signs

When hydronephrosis is absent, CT may demonstrate secondary signs of obstruction:

• Dense nephrogram: Increased parenchymal enhancement persisting into delayed phases
• Delayed pyelogram: Contrast excretion delayed relative to the contralateral kidney
• Perinephric stranding: Fat stranding around the kidney suggesting acute process
• Pyelosinus extravasation: Forniceal rupture from high collecting system pressure

The combination of dense nephrogram with delayed pyelogram was first described by Harrison et al. in 1979 as a marker of obstruction even when collecting system dilation is minimal (9).

⚠️ Warning: The combination of dense nephrogram with delayed pyelogram should raise suspicion for obstruction regardless of the appearance of the collecting systems (9).

7.1 Landmark Urology Publications with Full Abstracts and Analysis

Spital A, Valvo JR, Segal AJ. Nondilated obstructive uropathy. Urology. 1988;31(6):478-482. PMID: 3287742

Full Abstract: “Four patients presented with severe renal failure secondary to urinary tract obstruction, yet ultrasonography and/or computed tomography revealed only minimal dilatation in 1 patient and no dilatation in the other three. Two patients had prostate cancer, one had bladder cancer, and one had retroperitoneal fibrosis. In all cases, relief of obstruction led to a dramatic improvement in renal function. These cases, and others in the literature, illustrate that in certain settings severe urinary tract obstruction may be present in the absence of dilatation and hence may be missed by noninvasive imaging techniques. Nondilated obstructive uropathy should be suspected in any elderly patient who presents with the acute onset of oliguria in the absence of an identifiable cause, especially if there is a previous history of malignancy in the pelvis.”

Analysis: This foundational 1988 paper from the journal Urology—not a nephrology or radiology journal—established the entity of NDOU in the surgical subspecialty literature. Several points deserve emphasis. First, only one of four patients had retroperitoneal fibrosis; the other three had common genitourinary malignancies (prostate and bladder cancer) that typically cause classic hydronephrosis. Second, the authors explicitly state that obstruction “may be missed by noninvasive imaging techniques”—acknowledging the limitation of relying solely on ultrasound or CT. Third, the paper provides a clinical pearl for when to suspect NDOU: elderly patients with acute oliguria and history of pelvic malignancy. This paper remains the single most cited reference in the NDOU literature and establishes that urologists themselves have recognized this entity for over 35 years.

Kocurek JN, Orihuela E, Saltzstein DR. Nondilated obstructive uropathy and renal failure as a result of carcinoma of the intrapelvic area. Surg Gynecol Obstet. 1991;173(6):470-472. PMID: 1948605

Full Abstract: “Renal failure secondary to obstruction of the urinary tract can sometimes present with only minimal or even no dilatation of the proximal part of the urinary tract; this is especially true when a history of malignancy within the pelvic area exists. Approximately 4 per cent of the patients who present with renal failure because of obstructive uropathy do so with minimal or no dilatation. Of these, approximately 60 per cent are associated with an intrapelvic malignancy. When a patient with renal failure presents with the associated findings of an intrapelvic or retroperitoneal tumor, it is imperative that obstructive uropathy be ruled out, even in the absence of dilatation.”

Analysis: Published by urologists Kocurek, Orihuela, and Saltzstein, this review provides the most commonly cited prevalence estimates for NDOU: 4% of all obstructive uropathy cases, with 60% of those associated with intrapelvic malignancy. The paper explicitly states that it is “imperative” to rule out obstruction “even in the absence of dilatation” when malignancy is present. This is a strong statement from surgical specialists acknowledging that negative imaging cannot exclude obstruction in high-risk patients. The phrase “imperative” carries particular weight—this is not presented as optional workup but as mandatory evaluation regardless of imaging findings. When encountering resistance from urology colleagues, citing this paper directly (“Kocurek et al. in Surgery, Gynecology & Obstetrics stated it is ‘imperative’ to rule out obstruction in patients with renal failure and intrapelvic malignancy, even without dilation”) can be an effective communication strategy.

Spital A. Nondilated Obstructive Uropathy – Still Underappreciated. Urology. 2020;143:272. PMID: 32504684

Full Abstract: No abstract available (editorial/commentary format).

Analysis: Published in 2020—32 years after his original 1988 paper—Aaron Spital returned to the pages of Urology to emphasize that NDOU remains “still underappreciated.” The choice of title is significant: despite decades of published literature, case reports, and review articles, clinicians continue to miss this diagnosis. The publication of this piece in a major urology journal confirms that the problem persists even among specialists trained to evaluate urinary tract obstruction. This editorial serves as a contemporaneous reminder that the cognitive bias toward requiring visible hydronephrosis to diagnose obstruction remains prevalent. The fact that Urology published this commentary 32 years after Spital’s original paper demonstrates both the longevity of his observation and the persistent nature of the problem.

Harrison RB, Widner LA, Johnstone WH, Wyker AW Jr. Subtle obstructive uropathy resulting from encasement of the ureters by tumor. J Urol. 1979;122(6):835-836. PMID: 583167

Full Abstract: “The diagnosis of obstructive uropathy may be difficult in the occasional case in which there is little or no dilatation of the collecting system. A case is presented in which anuric renal failure resulted from encasement of the ureters by tumor. The excretory urogram revealed a delayed pyelogram and a dense nephrogram with minimal dilatation of the collecting systems. The combination of a dense nephrogram and delayed pyelogram should raise the possibility of obstruction, regardless of the appearance of the collecting systems.”

Analysis: This early 1979 paper from The Journal of Urology—preceding Spital’s work by nearly a decade—introduced the radiographic finding of “dense nephrogram with delayed pyelogram” as a marker of obstruction even when collecting system dilation is minimal or absent. The authors explicitly stated that clinicians should consider obstruction “regardless of the appearance of the collecting systems.” This paper predates both Spital’s 1988 work and widespread CT imaging, demonstrating that the phenomenon of NDOU has been recognized for over four decades. The radiographic pearl of dense nephrogram with delayed pyelogram remains clinically relevant in the CT era and should prompt further investigation even when hydronephrosis is absent.

7.2 Literature Quality Analysis

The evidence base for NDOU consists primarily of case reports and small case series. The 2024 CKJ systematic review by Feliciangeli et al. represents the most comprehensive analysis to date, identifying only 49 patients across 23 publications over 44 years (1). Several limitations affect the literature:

• Publication bias: Cases are reported because they are unexpected; the true denominator of missed diagnoses is unknown
• Confirmation bias: Diagnosed cases require definitive testing; patients who never receive retrograde/antegrade pyelography cannot be counted
• Inconsistent definitions: Some studies define NDOU as “no hydronephrosis” while others include “minimal dilation”
• Heterogeneous populations: Case series mix malignancy, stones, and retroperitoneal fibrosis with different pathophysiology

Despite these limitations, the consistency of the phenomenon across decades, institutions, and etiologies supports the validity of NDOU as a clinical entity. The publication of case series in urology journals by urologists provides internal validation from the specialty most equipped to evaluate urinary tract obstruction.

7.3 Documented Urology Skepticism: Case Examples from the Literature

The literature contains explicit documentation of urology declining intervention despite clinical suspicion for NDOU:

Case 1 (Onuigbo et al., 2010): “In the second of our three reported patients in 2010, Urology was not convinced of the need for any further therapeutic intervention for suspected NDON-NDOU. The excellent corroborative relationship that had existed between Nephrology and Interventional Radiology was the driver for Interventional Radiology to agree to place a percutaneous left nephrostomy tube.” The result? “That fortuitous intervention turned out to confirm the diagnosis of NDON-NDOU and the rapid drop in serum creatinine from 392 umol/L to 103 umol/L within 24 hours of the percutaneous nephrostomy procedure” (17).

Case 2 (El-Alali et al.): “Urology was consulted to evaluate for postrenal obstruction, and they were reluctant to be involved in the care of this patient without objective evidence of urinary obstruction.” Only after clinical deterioration and nephrology persistence was cystoscopy performed, ultimately confirming bilateral ureteral obstruction (18).

⚠️ Warning: When urology is not convinced but clinical suspicion remains high, consider direct communication with interventional radiology for nephrostomy placement. The diagnosis can be confirmed or excluded empirically (17).

7.4 Understanding Urology Skepticism

Urology skepticism is understandable from a training perspective. Urologists are surgical specialists whose entire approach to obstruction is predicated on identifying a problem amenable to procedural intervention. Hydronephrosis serves as the “target” that justifies intervention. When that target is absent, the indication for invasive procedures becomes less clear.

Furthermore, retrograde pyelography and cystoscopy are not without risk: anesthesia, instrumentation trauma, infection, and ureteral perforation are all potential complications. Proceeding to these procedures without imaging evidence of obstruction requires confidence in clinical judgment over objective findings—a difficult position for any specialist.

The solution is not to criticize urology colleagues but to provide them with the clinical context and literature support needed to make an informed decision. Citing the urology literature directly demonstrates that the request is grounded in evidence from their own specialty.

Clinical Pearl: When consulting urology for possible NDOU, provide clinical context explicitly and cite the literature: “This patient has [high-risk features] with unexplained severe AKI. The Urology literature (Spital et al., Urology 1988; Kocurek et al., 1991) documents that 4–5% of obstructive uropathy presents without hydronephrosis. Kocurek stated it is ‘imperative’ to rule out obstruction in patients with pelvic malignancy even without dilation. I request definitive evaluation with retrograde pyelography.”

8.1 Clinical Scenario

The typical patient is an elderly male with known BPH, progressive urinary symptoms, and presentation with AKI. Ultrasound demonstrates a markedly distended bladder (PVR > 500 mL or even > 1 L) but no hydronephrosis. Catheter placement drains large volumes of urine. The question arises: will renal function improve with drainage alone, or has chronic obstruction already caused irreversible injury?

8.2 Evidence Base: Limited but Supportive

The evidence supporting renal function recovery after relief of chronic bladder outlet obstruction is derived primarily from observational studies and retrospective case series. Notably, most of these studies evaluated patients WITH hydronephrosis at baseline, making direct extrapolation to the NDOU scenario uncertain.

Key findings from the literature on chronic retention and renal recovery:

• Patients with bilateral hydronephrosis and elevated creatinine from chronic retention demonstrate significant renal function improvement after TURP in most series (19,20)
• The presence of hydronephrosis at baseline is associated with greater absolute improvement in creatinine after intervention, likely because there is more reversible component (19)
• Patients without hydronephrosis but with elevated PVR represent an understudied population; most large series either excluded these patients or did not separately analyze outcomes
• Post-obstructive diuresis after catheter placement provides indirect evidence of functional obstruction and is associated with renal recovery (21)

8.3 The Evidence Gap

The specific question—does renal function improve in patients with chronic retention, high PVR, AKI, and NO hydronephrosis—has not been directly addressed in prospective studies. The available evidence is largely clinical observation:

• Clinicians report improvement in creatinine after catheterization in this population, but published series specifically isolating these patients are lacking
• The pathophysiology would suggest that if the AKI is due to bladder-level obstruction impairing renal function (even without visible upper tract dilation), relief should improve function
• The absence of hydronephrosis may indicate a compliant upper tract that decompresses into the distended bladder, but this does not preclude functional obstruction

In summary, the improvement observed in these patients is supported by physiologic reasoning and clinical experience but lacks the high-quality evidence of prospective trials. Most nephrologists and urologists would agree that a trial of catheter drainage is low-risk and reasonable, but the predictive factors for recovery are not well-defined.

Clinical Pearl: In patients with chronic retention, high PVR, and AKI without hydronephrosis, a trial of bladder drainage is reasonable. Post-obstructive diuresis after catheterization suggests functional obstruction and is associated with renal recovery. However, the evidence base for this specific population is limited to clinical observation rather than prospective data (19–21).

9.1 Diagnostic Approach

When NDOU is suspected, the following approach is recommended:

• Assess for high-risk features: pelvic malignancy, recent stone passage, retroperitoneal process, severe unexplained oliguria/anuria
• Review imaging critically for secondary signs: perinephric stranding, dense nephrogram, delayed pyelogram, asymmetric enhancement
• Consider Doppler RI if available, recognizing its limitations
• If clinical suspicion remains high despite negative imaging, proceed to definitive testing

9.2 Definitive Testing

Options for definitive evaluation include:

• Retrograde pyelography: Performed by urology, allows direct visualization and potential intervention
• Antegrade pyelography: Performed by interventional radiology, can be combined with nephrostomy placement
• Empiric nephrostomy: In critically ill patients with high suspicion, therapeutic trial of drainage may be diagnostic

9.3 Communication Strategy

Effective interdisciplinary communication is essential. When consulting urology or IR, provide:

• Specific high-risk features present in this patient
• Summary of current renal function and trajectory
• Explicit citation of the urology literature supporting NDOU
• Clear statement of the requested intervention

⚠️ Warning: Missing the diagnosis of NDOU converts a potentially reversible cause of AKI into permanent kidney failure. When clinical suspicion is high, advocate persistently for definitive testing (5,6,17,18).